Drugging the myofibroblast: a new approach to treating fibrosis.
Location: United States
Total raised: $257M
Founded date: 2019
Investors 3
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| - | Ono Ventur... | onoventure... |
| 23.03.2023 | GIMV | gimv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 09.06.2026 | Series B | $76M | - |
| 07.01.2026 | Series B | $76M | Longwood F... |
| 15.03.2023 | - | $105M | Sofinnova ... |
Mentions in press and media 14
| Date | Title | Description |
| 09.09.2026 | Mediar Therapeutics Enters into a Collaboration and Option Agreement with Ono Pharma to Develop NovelTreatments for Fibro-inflammatory Diseases | - |
| 09.06.2026 | Ono Venture Investment makes a follow-on investment in Mediar Therapeutics. (Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibr... | - |
| 08.01.2026 | Mediar Therapeutics Secures $76M to Advance Fibrosis Therapies | Mediar Therapeutics secured a substantial $76 million in Series B financing. This Boston-based biotechnology firm is advancing novel, first-in-class therapies to combat fibrosis. The funding fuels its clinical pipeline. Key programs include... |
| 07.01.2026 | Mediar Therapeutics: $76 Million Series B Raised As Fibrosis Programs Advance | Mediar Therapeutics, a clinical-stage biotech developing first-in-class therapies designed to halt fibrosis, said it closed an oversubscribed $76 million Series B financing co-led by Amplitude Ventures and ICG as it advances a portfolio of ... |
| 07.01.2026 | Mediar Therapeutics Raises $76M in Series B Financing | Mediar Therapeutics, Inc., a Boston, MA-based clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, raised $76m in Series B financing. The round was co-led by Amplitude Ventures and ICG, with par... |
| 07.08.2024 | Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis | First cohort of participants dosed in Phase 1 trial evaluating safety and tolerability of MTX-474, a human IgG1 antibody designed to neutralize EphrinB2 signaling Phase 1 study for MTX-463, an antibody neutralizing WISP1-mediated fibrotic s... |
| 04.04.2023 | Latest Updates of 6 Viva's Portfolio Companies | HONG KONG, April 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies... |
| 15.03.2023 | Mediar Therapeutics Raises $105M in Funding | Mediar Therapeutics, a Cambridge, MA-based biotechnology company, raised $105M in funding. The round was led by Novartis Venture Fund and Sofinnova Partners with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol ... |
| 17.03.2021 | Mediar Therapeutics : Adds New Investors As It Advances Anti-Fibrotic Treatments | Mediar Therapeutics today announced the completion of a seed extension funding round and welcomed Pfizer Ventures and Ono Venture Investment (OVI) as new syndicate members. Mediar, a discovery-stage company developing new treatments for fib... |
| 17.03.2021 | Mediar Therapeutics Adds New Investors As It Advances Anti-Fibrotic Treatments | CAMBRIDGE, Mass.–(BUSINESS WIRE)–March 17, 2021– Mediar Therapeutics today announced the completion of a seed extension funding round and welcomed Pfizer Ventures and Ono Venture Investment (OVI) as new syndicate members. Mediar, a discover... |
Show more